Development, manufacturing, marketing and distribution exclusively of highly sophisticated best quality synthetic hyaluronic acids for orthopedics, cosmetics, ophthalmology. Distribution net in almost 70 countries worldwide. Manufacturing place ISO/GMP approved making solely hyaluronic acids since 26 years.
Absolutely highest quality Qualitative deficiencies of synovial fluids in all joints may be very efficiently supplemented by ViscoPlus® high molecular hyaluronic acid of > 2.5 MDa resulting in much better lubrication and shock absorbing effect. ViscoPlus® Gel is highly concentrated new high molecular weight 3,0 MDa formulae that allows therapy by only 1 infiltration. Further developement ViscoPlus®Matrix high molecular matrix offering longer lasting effect up to 1 year with single infiltration.
Viscobella® is high molecular weight, stabilised revitalisation and rejuvenation gel for dermal treatment of various facial wrinkles, lips and facial augmentation. Viscobella® modified molecules give more elastic and natural effect.
Paramount orthopedic high molecular hyaluronic acid ViscoPlus® > 2.5 MDa, quality adopted to that of synovial fluid resulting in much better lubrication and shock absorbing effect and long term ease of pain
ViscoPlus® Gel is highly concentrated new high molecular weight 3,0 MDa formulae that allows therapy by only 1 infiltration.Quality adopted to that of synovial fluid resulting in much better lubrication and shock absorbing effect and long term ease of pain
synthetic highly biocompatible injectable stabilized and highly purified dermal hyaluronic acid, structurally identical to the body’s own hyaluronic acid, for a natural and safe way to revitalise and smooth your skin, to support your dermal structure to restore its natural appearance.
Viscobella made to even out facial deficiencies, for correction and shaping of moderately deep to deep wrinkles and folds, and for facial contouring.
Phone: +49 163 8815481
E-mail: Send message
long term extremely durable and stabilised hyaluronic acid for treatment of osteoarthritis in single injection ViscoPlus Matrix developed at our laboratory over last 3 years will be introduced in the last quarter of 2018.